These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combination echinocandin-polyene treatment of murine mucormycosis. Ibrahim AS; Gebremariam T; Fu Y; Edwards JE; Spellberg B Antimicrob Agents Chemother; 2008 Apr; 52(4):1556-8. PubMed ID: 18212099 [TBL] [Abstract][Full Text] [Related]
3. Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19. Shakrawal J; Sharma V; Goyal A; Kumar D; Meena S; Tiwari S; Jain V; Elhence P; Soni K; Choudhury B; Bhatnagar K; Garg MK; Misra S Int Ophthalmol; 2023 Jun; 43(6):1919-1926. PubMed ID: 36427099 [TBL] [Abstract][Full Text] [Related]
4. A mucormycosis case treated with a combination of caspofungin and amphotericin B. Kazak E; Aslan E; Akalın H; Saraydaroğlu O; Hakyemez B; Erişen L; Yazıcı B; Gürcüoğlu E; Yılmaz E; Ener B; Helvacı S J Mycol Med; 2013 Sep; 23(3):179-84. PubMed ID: 23856448 [TBL] [Abstract][Full Text] [Related]
5. Outcomes and factors affecting them in patients with rhino-orbito-cerebral mucormycosis. Kashkouli MB; Abdolalizadeh P; Oghazian M; Hadi Y; Karimi N; Ghazizadeh M Br J Ophthalmol; 2019 Oct; 103(10):1460-1465. PubMed ID: 30514712 [TBL] [Abstract][Full Text] [Related]
6. Breaking the Mold: A Review of Mucormycosis and Current Pharmacological Treatment Options. Riley TT; Muzny CA; Swiatlo E; Legendre DP Ann Pharmacother; 2016 Sep; 50(9):747-57. PubMed ID: 27307416 [TBL] [Abstract][Full Text] [Related]
7. COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis. Bhattacharyya A; Sarma P; Kaur H; Kumar S; Bhattacharyya J; Prajapat M; Prakash A; Sharma S; Reddy DH; Thota P; Bansal S; Gautam BS; Medhi B Indian J Pharmacol; 2021; 53(6):499-510. PubMed ID: 34975140 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin. Ogawa T; Takezawa K; Tojima I; Shibayama M; Kouzaki H; Ishida M; Okabe H; Shimizu T Auris Nasus Larynx; 2012 Apr; 39(2):224-8. PubMed ID: 21592699 [TBL] [Abstract][Full Text] [Related]
10. [Successful treatment of a persistent rhino-cerebral mucormycosis in a pediatric patient with a debut of acute lymphoblastic leukemia]. Cofré F; Villarroel M; Castellón L; Santolaya ME Rev Chilena Infectol; 2015 Aug; 32(4):458-63. PubMed ID: 26436794 [TBL] [Abstract][Full Text] [Related]
11. Combined antifungal treatment of visceral mucormycosis with caspofungin and liposomal amphotericin B. Voitl P; Scheibenpflug C; Weber T; Janata O; Rokitansky AM Eur J Clin Microbiol Infect Dis; 2002 Aug; 21(8):632-4. PubMed ID: 12226700 [No Abstract] [Full Text] [Related]
12. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Manesh A; John AO; Mathew B; Varghese L; Rupa V; Zachariah A; Varghese GM Mycoses; 2016 Dec; 59(12):765-772. PubMed ID: 27443253 [TBL] [Abstract][Full Text] [Related]
13. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300 [TBL] [Abstract][Full Text] [Related]
14. Transcutaneous retrobulbar amphotericin B for rhino-orbital-cerebral mucormycosis: a multi-center retrospective comparative study. Dallalzadeh LO; Ediriwickrema LS; Fung SE; Men CJ; Kossler AL; Kupcha AC; Mawn LA; Burkat CN; van Landingham SW; Conger JR; Simmons B; Pham C; Akella SS; Setabutr P; Ho T; Couch SM; Kim JS; Demirci H; Korn BS; Kikkawa DO; Liu CY Orbit; 2024 Feb; 43(1):41-48. PubMed ID: 36880205 [TBL] [Abstract][Full Text] [Related]
15. Antifungal combinations in Mucorales: A microbiological perspective. Schwarz P; Cornely OA; Dannaoui E Mycoses; 2019 Sep; 62(9):746-760. PubMed ID: 30830980 [TBL] [Abstract][Full Text] [Related]
16. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Spellberg B; Fu Y; Edwards JE; Ibrahim AS Antimicrob Agents Chemother; 2005 Feb; 49(2):830-2. PubMed ID: 15673781 [TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Groll AH; Silling G; Young C; Schwerdtfeger R; Ostermann H; Heinz WJ; Gerss J; Kolve H; Lanvers-Kaminsky C; Vieira Pinheiro JP; Gammelin S; Cornely OA; Wuerthwein G Antimicrob Agents Chemother; 2010 Oct; 54(10):4143-9. PubMed ID: 20660670 [TBL] [Abstract][Full Text] [Related]
19. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: a prospective cohort study. Manesh A; Devasagayam E; Bhanuprasad K; Varghese L; Kurien R; Cherian LM; Dayanand D; George MM; Kumar SS; Karthik R; Vanjare H; Peter J; Michael JS; Thomas M; Mathew BS; Samuel P; Peerawaranun P; Mukaka M; Rupa V; Varghese GM Clin Microbiol Infect; 2023 Oct; 29(10):1298-1305. PubMed ID: 37348653 [TBL] [Abstract][Full Text] [Related]
20. Intraconal amphotericin B for the treatment of rhino-orbital mucormycosis. Luna JD; Ponssa XS; Rodríguez SD; Luna NC; Juárez CP Ophthalmic Surg Lasers; 1996 Aug; 27(8):706-8. PubMed ID: 8858637 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]